{"id":"https://openalex.org/W4394458587","doi":"https://doi.org/10.6084/m9.figshare.5702179","title":"Supplementary Material for: Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial","display_name":"Supplementary Material for: Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial","publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W4394458587","doi":"https://doi.org/10.6084/m9.figshare.5702179"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/5702179","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Change_in_Hemoglobin_Trajectory_and_Darbepoetin_Dose_Approaching_End-Stage_Renal_Disease_Data_from_the_Trial_to_Reduce_Cardiovascular_Events_with_Aranesp_Therapy_Trial/5702179","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Change_in_Hemoglobin_Trajectory_and_Darbepoetin_Dose_Approaching_End-Stage_Renal_Disease_Data_from_the_Trial_to_Reduce_Cardiovascular_Events_with_Aranesp_Therapy_Trial/5702179","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026748157","display_name":"Finnian R. Mc Causland","orcid":"https://orcid.org/0000-0002-0299-0533","observed_orcids":["https://orcid.org/0000-0002-0299-0533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mc Causland, F.R.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010456790","display_name":"Brian Lee Claggett","orcid":"https://orcid.org/0000-0002-4215-9218","observed_orcids":["https://orcid.org/0000-0002-4215-9218","https://orcid.org/0009-0009-1748-4340"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claggett, B.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031560506","display_name":"Marc Alan Pfeffer","orcid":"https://orcid.org/0000-0003-3876-7568","observed_orcids":["https://orcid.org/0000-0003-3876-7568"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pfeffer, M.A.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068747774","display_name":"Emmanuel A. Burdmann","orcid":"https://orcid.org/0000-0002-7644-8579","observed_orcids":["https://orcid.org/0000-0002-7644-8579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Burdmann, E.A.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066841350","display_name":"Kai\u2010Uwe Eckardt","orcid":"https://orcid.org/0000-0003-3823-0920","observed_orcids":["https://orcid.org/0000-0003-3823-0920","https://orcid.org/0000-0001-8345-4371"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eckardt, K.-U.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032690087","display_name":"Andrew S. Levey","orcid":"https://orcid.org/0000-0003-1491-501X","observed_orcids":["https://orcid.org/0000-0003-1491-501X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Levey, A.S.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101330938","display_name":"McMurray J.J.V.","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"McMurray J.J.V.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023556434","display_name":"Giuseppe Remuzzi","orcid":"https://orcid.org/0000-0002-6194-3446","observed_orcids":["https://orcid.org/0000-0002-6194-3446"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Remuzzi, G.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100727879","display_name":"Ajay K. Singh","orcid":"https://orcid.org/0000-0003-2933-4058","observed_orcids":["https://orcid.org/0000-0003-2933-4058"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Singh, A.K.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054830306","display_name":"Scott David Solomon","orcid":"https://orcid.org/0000-0003-3698-9597","observed_orcids":["https://orcid.org/0000-0003-3698-9597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Solomon, S.D.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008309890","display_name":"Robert D. Toto","orcid":"https://orcid.org/0000-0001-9531-1749","observed_orcids":["https://orcid.org/0000-0001-9531-1749"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Toto, R.D.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110218161","display_name":"Patrick S. Parfrey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Parfrey, P.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10291","display_name":"Dialysis and Renal Disease Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/darbepoetin-alfa","display_name":"darbepoetin alfa","score":0.7850000262260437},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9860000014305115},{"id":"https://openalex.org/keywords/anemia-of-chronic-kidney-disease","display_name":"anemia of chronic kidney disease","score":0.949999988079071},{"id":"https://openalex.org/keywords/erythropoiesis-stimulating-agents","display_name":"erythropoiesis-stimulating agents","score":0.8610000014305115},{"id":"https://openalex.org/keywords/ferritin","display_name":"ferritin","score":0.6060000061988831},{"id":"https://openalex.org/keywords/transferrin-saturation","display_name":"transferrin saturation","score":0.996999979019165},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.9980000257492065},{"id":"https://openalex.org/keywords/iron-deficiency","display_name":"iron deficiency","score":0.8629999756813049},{"id":"https://openalex.org/keywords/erythropoietin-resistance","display_name":"erythropoietin resistance","score":0.9309999942779541},{"id":"https://openalex.org/keywords/treat-trial","display_name":"TREAT trial","score":0.796999990940094},{"id":"https://openalex.org/keywords/cardiovascular-events","display_name":"cardiovascular events","score":0.4869999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.667604923248291},{"id":"https://openalex.org/C3019040382","wikidata":"https://www.wikidata.org/wiki/Q476921","display_name":"End stage renal disease","level":3,"score":0.5615571737289429},{"id":"https://openalex.org/C2781404941","wikidata":"https://www.wikidata.org/wiki/Q2178381","display_name":"Darbepoetin alfa","level":3,"score":0.5516024827957153},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3637336492538452},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.33605289459228516},{"id":"https://openalex.org/C2778917026","wikidata":"https://www.wikidata.org/wiki/Q43041","display_name":"Hemoglobin","level":2,"score":0.32818323373794556},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2593032717704773}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/5702179","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Change_in_Hemoglobin_Trajectory_and_Darbepoetin_Dose_Approaching_End-Stage_Renal_Disease_Data_from_the_Trial_to_Reduce_Cardiovascular_Events_with_Aranesp_Therapy_Trial/5702179","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.5702179","doi":"https://doi.org/10.6084/m9.figshare.5702179","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.5702179","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.5702179.v1","doi":"https://doi.org/10.6084/m9.figshare.5702179.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.5702179.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/5702179","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Change_in_Hemoglobin_Trajectory_and_Darbepoetin_Dose_Approaching_End-Stage_Renal_Disease_Data_from_the_Trial_to_Reduce_Cardiovascular_Events_with_Aranesp_Therapy_Trial/5702179","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2774014067","https://openalex.org/W1964852190","https://openalex.org/W2767649990","https://openalex.org/W4253975515","https://openalex.org/W4255731193","https://openalex.org/W2170724586","https://openalex.org/W2162009787","https://openalex.org/W2016532897","https://openalex.org/W2046224330","https://openalex.org/W2407470193"],"abstract_inverted_index":{"Background:":[0],"The":[1,228],"pathogenesis":[2],"of":[3,15,29,66,82,84,129,132,160,162,195,207,220,225,242,245],"chronic":[4],"kidney":[5],"disease":[6,90],"associated":[7],"anemia":[8],"is":[9],"multifactorial":[10],"and":[11,21,45,105,113,135,169,176,182,199,247],"includes":[12],"decreased":[13],"production":[14],"erythropoietin":[16],"(EPO),":[17],"iron":[18,226],"deficiency,":[19],"inflammation,":[20],"EPO":[22],"resistance.":[23],"To":[24],"better":[25],"understand":[26],"the":[27,49,80,99,123,127,158,165,192,218,234],"trajectory":[28,81],"these":[30],"parameters,":[31],"we":[32],"described":[33],"temporal":[34,193],"trends":[35],"in":[36,48,69,102,107,122,147,205,233,248,253],"hemoglobin":[37],"(Hb),":[38],"ferritin,":[39],"transferrin":[40,177],"saturation,":[41],"C-reactive":[42],"protein":[43],"(CRP),":[44],"darbepoetin":[46,167,197,246],"dosing":[47],"Trial":[50],"to":[51,78,87,97,126,144,217,238],"Reduce":[52],"cardiovascular":[53],"Events":[54],"with":[55,250],"Aranesp":[56],"Therapy":[57],"(TREAT).":[58],"Methods:":[59],"We":[60],"performed":[61],"a":[62],"post":[63],"hoc":[64],"analysis":[65],"4,038":[67],"participants":[68,206],"TREAT.":[70,208],"Mixed":[71],"effects":[72],"linear":[73],"regression":[74],"models":[75],"were":[76,95,179],"used":[77,96],"determine":[79,98],"parameters":[83,201],"interest":[85],"prior":[86,125,216,237],"end-stage":[88],"renal":[89],"(ESRD).":[91],"Likelihood":[92],"ratio":[93],"tests":[94],"overall":[100],"differences":[101,106],"biomarker":[103],"values":[104],"trajectories":[108],"between":[109],"those":[110,148,153],"who":[111,149,154],"did":[112,114,155],"not":[115],"develop":[116],"ESRD.":[117],"Results:":[118],"Hb":[119,209],"declined":[120,210],"precipitously":[121],"year":[124],"development":[128,219],"ESRD":[130,151,203],"(irrespective":[131],"treatment":[133],"assignment),":[134],"was":[136],"on":[137],"average":[138],"1.15":[139],"g/dL":[140],"(95%":[141],"CI":[142],"\u20131.26":[143],"\u20131.04)":[145],"lower":[146],"developed":[150],"versus":[152],"not,":[156],"at":[157],"time":[159],"ESRD/end":[161],"follow-up.":[163],"Simultaneously,":[164],"mean":[166],"dose":[168],"CRP":[170],"concentration":[171],"increased,":[172],"while":[173],"serum":[174],"ferritin":[175],"saturations":[178],">140":[180],"\u03bcg/L":[181],"20%,":[183],"respectively.":[184],"Conclusions:":[185],"Our":[186],"analyses":[187],"provide":[188],"descriptive":[189],"insights":[190],"regarding":[191],"changes":[194],"Hb,":[196],"dose,":[198],"related":[200],"as":[202,211,213],"approaches":[204],"much":[212],"1\u20132":[214],"years":[215],"ESRD,":[221,239],"without":[222],"biochemical":[223],"evidence":[224],"deficiency.":[227],"most":[229],"precipitous":[230],"decline":[231],"occurred":[232],"months":[235],"immediately":[236],"despite":[240],"administration":[241],"escalating":[243],"doses":[244],"parallel":[249],"an":[251],"increase":[252],"CRP.":[254]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2024-04-08T00:00:00"}